Apply to Join Medixlinx

§0.1. Provider

• “Provider” means the individual clinician, practice, clinic, office, facility, professional entity, organizational unit, or care-delivering party applying to participate in the Medixlinx Protocol and, if accepted, entering into this Agreement with Medixlinx. A Provider may operate through one or more locations, offices, facilities, practitioners, brands, departments, or affiliated operational units. The term “Provider” shall not, by itself, be construed to mean that all such locations, affiliates, practitioners, departments, brands, or operational units are admitted into Medixlinx.

§0.2. Specialty Provider

• “Specialty Provider” means a Provider whose services are primarily organized around a defined specialty, subspecialty, discipline, or focused care category rather than broad general intake alone. A Specialty Provider may include, without limitation, specialty medical, specialty behavioral, specialty dental, specialty rehabilitative, specialty optical, or specialty veterinary providers.

§0.3. Multi-Location Provider

• “Multi-Location Provider” means a Provider that operates, controls, affiliates with, or presents services through more than one office, clinic, facility, location, branch, or other operational site, whether under one legal entity, multiple related entities, one brand, or multiple related brands.

§0.4. Larger Provider Group

• “Larger Provider Group” means a Provider or related Provider structure operating at a scale, organizational complexity, intake volume, geographic scope, or multi-practitioner level that Medixlinx reasonably classifies above the standard provider class for pricing, routing, operational, or participation purposes. A Larger Provider Group may include, without limitation, multi-site groups, larger specialty groups, affiliated provider networks, or other higher-capacity provider structures.

§0.5. Approved Participation Scope

• “Approved Participation Scope” means the specific operational unit or units of the Provider that Medixlinx has expressly approved in writing for participation in the Protocol. The Approved Participation Scope may consist of one provider, one single-location practice, one specifically identified location, one expressly identified set of locations, one designated intake unit, or another specifically approved operational scope. No broader organizational, affiliated, branded, departmental, practitioner-group, or future-expanded scope is included unless expressly approved by Medixlinx in writing.

§0.6. Approved Handoff Destination

• “Approved Handoff Destination” means the secure email address, webhook, agent endpoint, or other routing destination expressly designated by Medixlinx for receipt of handoffs solely for the Approved Participation Scope.

§1.1. Participation Framework

1. Medixlinx is a deterministic intake routing protocol for human and animal care. Providers applying to Medixlinx are applying to be evaluated for participation in that routing system, not for marketplace exposure, directory placement, lead purchase, or chatbot deployment.
2. Participation in Medixlinx is structured, reviewable, and conditional. It depends on organizational fit, operational clarity, routing compatibility, and continued compliance with the participation terms set out in this Provider Agreement.

§1.2. Nature of Participation

1. If accepted, a provider’s participation in Medixlinx will include a Medixlinx provider page, routing-related materials, secure intake handoff configuration, and other operational elements necessary to support validated intake routing.
2. Participation does not make the provider an owner, operator, employee, partner, or agent of Medixlinx. Medixlinx remains an independent routing protocol, and participation remains limited to the terms, functions, and operational relationships expressly described by Medixlinx.

§1.3. No Guarantee of Acceptance or Launch

1. Submission of an application to Medixlinx does not guarantee acceptance. Acceptance, if granted, does not guarantee immediate launch, immediate routing activity, or continued participation.
2. Medixlinx may accept, defer, reject, pause, or decline to launch any provider application or provider implementation where fit, readiness, accuracy, safety, technical compatibility, or protocol integrity issues arise.

§1.4. Test, Review, and Evaluation Periods

1. Medixlinx may review providers through pre-acceptance evaluation, page-configuration review, implementation review, and any approved limited test period. Where Medixlinx authorizes a test period, that test may be used to assess routing compatibility, operational responsiveness, endpoint readiness, and general provider fit within the protocol.
2. Any such review or test period remains conditional and does not guarantee continued participation after the test concludes. Medixlinx may refine, pause, extend, conclude, or decline further participation based on review findings.

§1.5. Commercial Structure

1. Unless otherwise stated by Medixlinx in writing, provider participation in Medixlinx is offered on a month-to-month basis at the then-current published monthly rates. At the time of this application, the published rates are the following, with no finite term:
   (1) $2,300.00 for the Foundational Rate;
   (2) $3,400.00 for the Standard Rate; and
   (3) $4,600.00 for the Advanced Rate.
2. The price of the Foundational Rate is reserved for the first 105 admitted providers and applies only to the specific approved participation scope granted at admission. It does not automatically extend to additional locations, affiliates, departments, practitioners, or later expansion. Standard and Advanced Rates apply according to provider class, participation scope, and Medixlinx’s published pricing structure at the time of admission or renewal.
3. The Standard and Advanced Rates apply to provider class, approved participation scope, and Medixlinx’s published pricing structure at the time of admission, continuation, or renewal.
4. Medixlinx may update published pricing, participation terms, or related operational conditions from time to time. Any such changes will not retroactively convert Medixlinx into a marketplace, directory, lead-generation service, or chatbot-based intake system.

§1.6. Continuing Status of Participation

1. Participation in Medixlinx is continuing only so long as the provider remains acceptable to Medixlinx under its routing, operational, technical, and representational standards. Continued participation depends on ongoing provider accuracy, cooperation, readiness, and compatibility with the Medixlinx protocol.
2. Medixlinx may review continued participation from time to time, including but not limited to review of provider data accuracy, service availability, intake responsiveness, routing compatibility, technical handoff readiness, participation scope, and adherence to the terms of this Agreement.
3. A provider’s acceptance into Medixlinx does not create a permanent right to remain in the protocol. Medixlinx may refine, pause, limit, extend, conclude, or decline further participation where it determines that continued participation is no longer appropriate, reliable, operationally workable, or aligned with the protocol.
4. Continued participation may also depend on the provider’s maintenance of accurate public and internal information, functional routing destinations, operational responsiveness, secure handoff readiness, and any other participation conditions reasonably required for deterministic intake routing.
5. If Medixlinx updates its pricing, operational terms, technical requirements, participation standards, or published structure, continued participation after such update may require provider compliance with the then-applicable terms, except where Medixlinx has expressly granted a protected or locked rate in writing. Nothing in this Agreement shall be interpreted to require Medixlinx to continue routing, maintain listing-style visibility, preserve a particular participation status, or retain a provider in the protocol where Medixlinx determines that continuation is no longer appropriate under its standards, structure, or operational judgment.

§2.1. Accuracy of Submitted Information

1. The provider represents that all information submitted to Medixlinx in connection with its application, evaluation, onboarding, setup, provider page, routing configuration, operational review, or continued participation is true, complete, and materially accurate at the time of submission.
2. This representation applies to all information submitted by or on behalf of the provider, whether delivered through:
   (1) The Medixlinx "Apply" page;
   (2) Email, forms, questionnaires, or intake fields;
   (3) Live calls, recorded calls, or meetings;
   (4) Written explanations, attachments, or uploaded documents;
   (5) Provider-page review comments or revision requests; and
   (6) Any other channel Medixlinx reasonably uses to assess or maintain Provider participation.
3. The provider shall not submit information that:
   (1) Omits a material fact needed to make the submission not misleading;
   (2) Creates a false or incomplete picture of the provider’s services, capacity, availability, scope, or operational readiness;
   (3) Inaccurately describes licensure, credentials, specialties, treatment categories, species served, service area, payer participation, scheduling method, or patient eligibility criteria;
   (4) Is presented in a manner likely to distort routing fitness.
4. The provider acknowledges that Medixlinx is a deterministic intake routing protocol and not a broad exposure system, and that Medixlinx may use the information submitted by the Provider to determine whether:
   (1) The provider qualifies for participation;
   (2) The provider can be structurally matched to specific intake types;
   (3) A provider page can be published or maintained;
   (4) Routing logic should be activated, limited, revised, or suspended;
   (5) A submission should be discarded as a mismatch.
5. The provider further represents that all submitted materials are provided in good faith to support accurate intake determination rather than marketing presentation, cosmetic positioning, or selective omission.

§2.2. Authority to Submit and Bind

1. The individual submitting an application, reviewing materials, approving provider-page content, supplying operational information, or otherwise acting on behalf of the provider represents that such individual is authorized to do so.
2. Such authority includes, as applicable, authority to:
   (1) Provide factual and operational information about the provider;
   (2) Respond to Medixlinx requests for clarification or correction;
   (3) Approve the provider’s inclusion, setup status, and routing-related configuration;
   (4) Authorize publication of provider-facing or patient-facing materials associated with participation; and
   (5) Bind the provider with respect to statements, confirmations, and approvals made during application, onboarding, and continuing participation.
3. If the submitting or responding individual is not the ultimate legal owner or final signatory for the provider entity, that individual nevertheless represents that they have sufficient delegated authority to communicate accurate information and to participate meaningfully in the Medixlinx review and setup process.
4. The provider shall not permit any person to submit information to Medixlinx on its behalf unless that person is appropriately informed and authorized with respect to the matters being submitted.
5. Upon request by Medixlinx, the provider shall reasonably identify the person or role serving as its authorized point of contact for:
   (1) Application matters;
   (2) Routing and intake-fit matters;
   (3) Provider-page review;
   (4) Technical or endpoint coordination; and
   (5) Ongoing operational updates.
6. If Medixlinx reasonably determines that a submission, approval, or instruction was made by a person lacking actual authority or sufficient organizational knowledge, Medixlinx may:
   (1) Disregard the submission or instruction;
   (2) Pause review or implementation;
   (3) Require reconfirmation by a properly authorized representative; or
   (4) Suspend further progress until authority is clarified.

§2.3. Organizational Status and Standing

1. The provider represents that it is a real and operating individual practice, group practice, facility, organization, or care entity lawfully offering the services it describes to Medixlinx.
2. The provider further represents that, to the extent applicable to its structure and jurisdiction:
   (1) It is duly organized, active, and in good standing;
   (2) It holds the licenses, registrations, permits, approvals, or professional authorizations reasonably necessary to provide the services described;
   (3) It is not materially misrepresenting its ownership, legal form, operating status, or service model; and
   (4) It is not presenting proposed, inactive, unavailable, or merely aspirational services as if they were current and operational.
3. The provider shall accurately identify the operational entity participating in Medixlinx, including where relevant:
   (1) The legal entity name;
   (2) The trade name or public-facing name;
   (3) The location or locations actually relevant to routing;
   (4) The human or animal care categories actually offered; and
   (5) The actual intake destination or workflow endpoint to which matched inquiries may be routed.
4. If the provider is part of a larger organization, management group, parent structure, franchise, affiliation network, or multi-location system, the provider shall not imply that Medixlinx participation applies more broadly than it actually does.
5. Participation in Medixlinx may be limited by Medixlinx to the specific entity, location, department, service line, specialty, clinician grouping, or operational unit actually reviewed and accepted.
6. The provider acknowledges that organizational identity and operational standing are not cosmetic matters within Medixlinx but core routing variables relevant to fit determination, launch readiness, and continued participation.

§2.4. Continuing Duty to Update

1. The provider has an ongoing duty to keep its submitted information materially current for so long as it is under review by Medixlinx, in setup with Medixlinx, published through Medixlinx, or otherwise participating in the Medixlinx protocol.
2. The provider shall notify Medixlinx within a commercially reasonable time if any previously submitted information becomes inaccurate, incomplete, outdated, or materially misleading.
3. This duty applies, without limitation, to changes involving:
   (1) Licensure, credentials, or professional standing;
   (2) Services offered, conditions treated, procedures performed, or species served;
   (3) Acceptance criteria, exclusions, or eligibility rules;
   (4) Locations, service areas, coverage areas, or scheduling territories;
   (5) Contact information, intake endpoints, forms, phone lines, or technical integrations;
   (6) Payer participation, self-pay structure, or referral requirements;
   (7) Hours, staffing, availability, or capacity constraints;
   (8) Organizational ownership, legal structure, or operating status; and
   (9) Any other matter reasonably likely to affect routing accuracy or participation fitness.
4. The provider shall not assume that previously accurate information remains acceptable once conditions materially change.
5. Where Medixlinx requests confirmation, correction, or recertification of submitted information, the provider shall respond within a commercially reasonable time and with sufficient specificity to permit continued evaluation or continued routing integrity.
6. Failure to update materially relevant information may be treated by Medixlinx as a representation failure even if the original submission was accurate when first made.

§2.5. Reliance by Medixlinx

1. The provider acknowledges that Medixlinx is entitled to rely on the truthfulness, completeness, and continuing accuracy of information submitted by the provider.
2. Such reliance may include use of submitted information for purposes including:
   (1) Evaluating whether the provider is eligible for participation;
   (2) Determining whether the provider is a fit for exact-match routing;
   (3) Constructing, refining, or limiting routing logic;
   (4) Preparing, publishing, revising, or maintaining the provider page;
   (5) Configuring routing endpoints or intake handoff structures;
   (6) Discarding mismatched intake pathways; and
   (7) Deciding whether participation should be maintained, suspended, narrowed, or terminated.
3. The provider acknowledges that Medixlinx does not operate as a broad listing surface in which minor inaccuracies can be tolerated as mere marketing defects. In the Medixlinx context, inaccurate information may alter routing outcomes and thereby affect patient or client fit, operational correctness, or system integrity.
4. Accordingly, the provider agrees that Medixlinx may treat factual accuracy, operational precision, and timely correction not as secondary administrative matters, but as foundational conditions of participation.
5. Medixlinx shall have no obligation to independently verify every representation made by the provider before relying on it. However, Medixlinx may request supporting clarification, correction, or substantiation where it deems appropriate.
6. Any review, editing, formatting, summarization, or re-expression by Medixlinx of provider-submitted information shall not reduce the provider’s responsibility for the underlying truth, completeness, and operational accuracy of that information.

§2.6. False, Misleading, or Outdated Representations

1. If the provider submits, approves, or permits the use of information that is false, materially incomplete, misleading, internally inconsistent, outdated, or otherwise unreliable, Medixlinx may take corrective action in its discretion.
2. Corrective action may include:
   (1) Requesting clarification, correction, or supporting documentation;
   (2) Delaying application review, setup, publication, or launch;
   (3) Declining to activate or continue routing;
   (4) Narrowing the provider’s participation scope;
   (5) Removing or withholding specific claims, service categories, or routing paths;
   (6) Suspending the provider from participation; or
   (7) Terminating the Provider’s participation altogether.
3. Medixlinx may take such action whether the issue arises:
   (1) Before acceptance;
   (2) During evaluation or testing;
   (3) During onboarding or setup;
   (4) After provider-page publication;
   (5) After routing has begun, or
   (6) After Medixlinx receives third-party information, internal findings, or operational signals suggesting that prior representations can no longer be relied upon.
4. A representation problem need not involve fraud to justify Medixlinx's action. Material carelessness, omission, failure to update, repeated inconsistency, or persistent non-responsiveness may be sufficient where routing integrity or system trustworthiness is affected.
5. Where the issue is curable, Medixlinx may, but is not required to, permit theprovider an opportunity to correct the problem before further action is taken.
6. The provider acknowledges that because Medixlinx depends on exact-fit routing and mismatch discard logic, false or outdated representations are not minor platform defects but direct threats to routing integrity, and may therefore justify immediate limitation, suspension, or termination of participation.

§3.1. Deterministic Routing Framework

1. Medixlinx operates as a deterministic intake routing protocol. It does not operate as a marketplace, listing service, referral directory, advertising surface, lead generator, or generalized exposure system for providers.
2. Accordingly, Medixlinx does not route inquiries by popularity, proximity alone, payment for placement, generalized visibility, random distribution, discretionary sales preference, or cosmetic profile quality.
3. Routing within Medixlinx is based on structured intake analysis against defined fit criteria established by Medixlinx using the information submitted by providers, the operational conditions applicable to the relevant provider page, and the routing rules then in force within the protocol.
4. The fact that a provider participates in Medixlinx does not mean that every intake associated with its general field, specialty, or service category will be routed to that provider.
5. Medixlinx may determine that a given intake:
   (1) Qualifies for routing to a particular provider;
   (2) Qualifies for routing only within a narrowed category or condition set;
   (3) Requires additional logic, clarification, or exclusion handling before routing;
   (4) Does not match the provider in question; or
   (5) Should be discarded, suppressed, or otherwise not routed through the protocol.
6. Each provider acknowledges that routing within Medixlinx is protocol-driven, exacting in structure, and dependent on fit integrity rather than mere participation status.

§3.2. Exact-Fit Matching Criteria

1. Medixlinx evaluates routing fitness by comparing intake information against the actual scope, constraints, and operational characteristics of the relevant provider as recognized by Medixlinx.
2. Such evaluation may include, without limitation, whether the provider is appropriate based on:
   (1) Service line, specialty, discipline, or treatment category;
   (2) Patient type, case type, condition type, or care context;
   (3) Species, breed category, or animal-care classification, where relevant;
   (4) Geography, service area, location, state, region, or routing territory;
   (5) Payer participation, payment structure, referral requirement, or financial eligibility rule;
   (6) Age group, case exclusion, risk category, care limitation, or intake threshold;
   (7) Operational days, hours, intake timing, scheduling pathway, or availability condition; and
   (8) Any other factor Medixlinx determines is materially relevant to routing correctness.
3. A provider shall not be treated as a fit merely because it appears broadly related to the intake category at issue.
4. Medixlinx may require alignment across multiple criteria before determining that an intake qualifies for routing.
5. Exact-fit within Medixlinx does not require philosophical perfection or universal compatibility. However, it requires a sufficiently precise structural match such that routing is operationally sensible, truthful, and appropriate within the protocol.
6. Each provider acknowledges that fit is determined by Medixlinx under protocol logic and not by the provider’s preferred self-description alone.

§3.3. Mismatch, Exclusion, and Discard Logic

1. If Medixlinx determines that an intake does not fit a provider’s actual service scope, constraints, declared parameters, or routing eligibility conditions, Medixlinx may decline to route that intake to the provider.
2. A mismatch may arise where an intake falls outside one or more material routing variables, including where:
   (1) The service requested is not actually offered;
   (2) The case type is excluded or not supported;
   (3) The geography does not fit the provider’s real operating area;
   (4) The payer or payment structure is incompatible;
   (5) The provider lacks the appropriate endpoint, readiness, or workflow for that intake type;
   (6) The provider’s declared criteria no longer match its operational reality; or
   (7) Medixlinx otherwise determines that routing would be inaccurate, strained, unreliable, or improper.
3. Medixlinx shall have no obligation to force, stretch, salvage, or artificially broaden a route merely because a provider participates in the protocol.
4. Where fit is absent, uncertain, degraded, or contradicted by available information, Medixlinx may:
   (1) Discard the intake from that provider’s routing path;
   (2) Suppress routing to that provider for the intake category at issue;
   (3) Hold the intake outside that route pending additional logic or review;
   (4) Narrow the applicable routing rules; or
   (5) Take any other routing-limiting action reasonably necessary to preserve fit integrity.
5. A provider shall not interpret non-routing, reduced routing, or routing exclusion as evidence of platform malfunction, unfair demotion, or breach of expected exposure, where the result reflects Medixlinx’s mismatch or exclusion logic.
6. Each provider acknowledges that mismatch discard logic is a core feature of Medixlinx, and not an incidental limitation of the system.

§3.4. Routing Limits and Provider Constraints

1. Routing through Medixlinx is limited by the actual conditions under which a provider can appropriately receive, evaluate, schedule, or otherwise handle the relevant intake.
2. Such limits may include, without limitation:
   (1) Service scope;
   (2) Specialty boundaries;
   (3) Intake exclusions;
   (4) Geographic reach;
   (5) Licensure or jurisdictional limits;
   (6) Payer or referral constraints;
   (7) Case complexity limits;
   (8) Endpoint format or technical pathway;
   (9) Hours of operation;
   (10) Staffing or workflow realities; and
   (11) Temporary or persistent capacity limitations.
3. Medixlinx may incorporate such limits into routing logic, whether they are permanent, conditional, time-sensitive, narrow, broad, or category-specific.
4. A provider shall not represent itself to Medixlinx in a broader manner than its actual operational capacity supports, and Medixlinx may narrow routing rules wherever actual constraints require narrower participation than outward positioning might suggest.
5. If Medixlinx determines that a provider’s real-world constraints materially limit fit, Medixlinx may reduce, condition, segment, pause, or decline routing accordingly.
6. Each provider acknowledges that routing volume, routing scope, and routing continuity may lawfully be limited by fit logic and provider-specific operational constraints, and are not guaranteed by mere inclusion in the protocol.

§3.5. No Ranking, Marketplace Placement, or Lead Distribution

1. Medixlinx does not sell ranking, sponsored placement, visibility boosts, preferential listing position, impression share, or lead priority within its routing logic.
2. Participation in Medixlinx does not entitle a provider to:
   (1) A higher position in any comparative display;
   (2) Rotation for the sake of fairness;
   (3) Exposure-based distribution of inquiries;
   (4) Traffic allocation based on subscription theatrics or platform gamification;
   (5) Routing based on profile polish, branding style, or marketing aggressiveness; or
   (6) Generalized access to intakes merely because those intakes fall somewhere within the provider’s broader field.
3. Medixlinx does not function as a bid system, lead exchange, promotional marketplace, or directory in which multiple providers compete for generalized patient or client attention within the protocol.
4. To the extent Medixlinx presents provider-facing or public-facing materials, such materials exist to support routing clarity, operational understanding, and exact-fit determination, not to create a browsable exposure environment of the kind associated with marketplace platforms.
5. No provider shall state or imply that participation in Medixlinx constitutes paid priority placement, lead purchase, preferred ranking, or a marketing advantage of the ordinary directory or marketplace type.
6. Each provider acknowledges that Medixlinx is structurally opposed to broad exposure logic and instead operates through route qualification, route exclusion, and fit-governed intake handling.

§3.6. Medixlinx Control of Routing Logic

1. Medixlinx retains sole authority to define, implement, refine, narrow, test, condition, suspend, or discontinue routing logic used within the protocol.
2. This authority includes, without limitation, the authority to:
   (1) Determine which routing variables are relevant;
   (2) Establish the level of precision required for fit;
   (3) Revise routing criteria as the protocol develops;
   (4) Segment providers by narrower operational categories;
   (5) Add, remove, tighten, or restructure exclusion rules;
   (6) Test routing logic before or after launch;
   (7) Pause routing pathways that appear unreliable or degraded; and
   (8) Decline routing where Medixlinx determines that fit integrity cannot be sufficiently maintained.
3. Medixlinx shall not be required to disclose all internal routing logic, rule weighting, protocol thresholds, or fit-decision mechanics merely because a provider participates in the system.
4. A provider may supply clarifying information relevant to fit, but no provider has the right to dictate how Medixlinx defines routing integrity, mismatch thresholds, or protocol-level inclusion rules.
5. Where Medixlinx determines that a routing path creates error risk, mismatch risk, operational strain, or structural incoherence, Medixlinx may modify or discontinue that path without treating the prior logic as permanently owed to the provider.
6. Each provider acknowledges that control over routing logic is fundamental to the Medixlinx protocol and necessary to preserve exact-fit routing, mismatch discard discipline, and overall system integrity.

§4.1. Required Provider Page and Participation Materials

1. Participation in Medixlinx requires a Provider Page and associated participation materials as a part of the provider’s operational presence within the Medixlinx protocol.
2. The Provider Page serves as the patient-facing destination associated with a provider’s participation in Medixlinx. For the patient or user, the experience may appear as a direct redirection or arrival at the Provider Page. Yet, the underlying routing, validation, fit determination, and handoff functions are performed by the Medixlinx protocol environment in the background.
3. Accordingly, the Provider Page is not a marketplace listing, directory placement, advertisement unit, promotional microsite, or generalized exposure surface. It is a structured Medixlinx page tied to deterministic intake routing and related protocol functions.
4. In addition to the Provider Page itself, participation materials may include:
   (1) A Medixlinx routing button for the provider’s website;
   (2) Social media linking where applicable;
   (3) A Medixlinx link and QR code for printed materials; and
   (4) Such other routing-facing or participation-facing materials as Medixlinx may require in connection with setup, routing access, handoff continuity, or protocol consistency.
5. The Provider Page and associated participation materials exist to support structured provider representation, patient-facing access, routing recognition, intake continuity, and the proper operation of the Medixlinx protocol environment.
6. Each provider acknowledges that the Provider Page and associated participation materials form part of the required Medixlinx participation structure and are governed by Medixlinx protocol standards rather than by provider marketing preference alone.

§4.2. Provider Materials and Source Content

1. In connection with the creation, maintenance, revision, and continued accuracy of the Provider Page and associated participation materials, Medixlinx may request or receive materials, data, statements, and other source content from providers.
2. Such source content may include, without limitation:
   (1) Practice or organization descriptions;
   (2) Specialty, service-line, or care-category descriptions;
   (3) Treatment, condition, or case-type information;
   (4) Species, animal care, or veterinary service information, where relevant;
   (5) Location, territory, or service-area information;
   (6) Payer, referral, or payment-related information;
   (7) Operational contact details, scheduling pathways, or intake endpoints;
   (8) Names, titles, credentials, biographies, and headshots;
   (9) Logos, photographs, or other brand-adjacent identifiers; and
   (10) Other materials Medixlinx reasonably considers relevant to provider representation, routing integrity, or setup.
3. Providers shall supply only materials they are authorized to provide and that are materially accurate, current, and suitable for use within Medixlinx.
4. Providers shall not submit materials that are false, misleading, unlawfully used, materially outdated, or structured in a way that distorts actual service scope, care fit, or operational readiness.
5. Submission of materials to Medixlinx does not require Medixlinx to use every submitted item, to preserve submitted wording, or to present materials in provider-preferred promotional form.
6. Each provider acknowledges that submitted materials may be used by Medixlinx not only for page drafting but also for fit review, routing evaluation, setup, handoff structuring, and continued participation assessment.

§4.3. Medixlinx Editorial and Structural Control

1. Medixlinx retains editorial, formatting, structural, presentational, and organizational control over the Provider Page and associated participation materials.
2. This control includes, without limitation, the right to:
   (1) Rewrite, condense, or standardize submitted language;
   (2) Reorganize content for clarity, readability, or routing coherence;
   (3) Apply uniform headings, layout, terminology, and structural conventions;
   (4) Remove promotional, exaggerated, vague, or non-operational claims;
   (5) Decline or limit materials that do not fit Medixlinx standards or protocol needs; and
   (6) Align the Provider Page and related materials with Medixlinx’s broader routing and presentation framework.
3. Medixlinx may present a provider in a narrower, more structured, or less promotional manner than the provider would independently prefer, where Medixlinx determines that such treatment better serves routing clarity, fit integrity, or system coherence.
4. Providers shall have no right to require verbatim use of submitted wording, unrestricted branding treatment, or page presentation designed primarily for self-promotional purposes.
5. Any review comments, correction requests, or factual clarifications about the provider may be considered by Medixlinx in good faith, but final editorial and structural decisions remain with Medixlinx.
6. Each provider acknowledges that Medixlinx editorial and structural control is a required feature of deterministic intake routing infrastructure and not evidence that the Provider Page is a jointly controlled marketing page.

§4.4. Accuracy, Review, and Correction of Page Content

1. Providers remain responsible for the substantive accuracy of provider-specific information supplied by or on behalf of the provider and used by Medixlinx in connection with the Provider Page and associated participation materials.
2. Medixlinx may request that a provider review draft page content, revised content, linking elements, routing references, or other provider-facing materials before or after publication or deployment.
3. Where Medixlinx requests review, confirmation, or correction, the provider shall respond within a commercially reasonable time and with sufficient specificity to permit accurate revision, continued setup, or continued routing use.
4. If a provider becomes aware that any Provider Page content or associated participation material is materially inaccurate, incomplete, outdated, or misleading, the provider shall notify Medixlinx within a commercially reasonable time.
5. Medixlinx may rely on a provider’s silence after a reasonable review opportunity as evidence that no material correction has been identified. Such silence does not eliminate the provider’s ongoing duty to report inaccuracies once known, however.
6. Each provider acknowledges that inaccuracies in the Provider Page or associated participation materials may affect routing integrity, handoff continuity, operational clarity, and continued participation within Medixlinx.

§4.5. Routing Button, Linking, and Printed Routing References

1. As part of participation in Medixlinx, each provider shall use, maintain, or permit, where applicable, certain Medixlinx-issued or Medixlinx-approved routing-facing references associated with the Provider Page.
2. Such routing-facing references may include:
   (1) A Medixlinx routing button for the provider’s website;
   (2) Social media linking where applicable;
   (3) A Medixlinx link for digital or public-facing reference;
   (4) A Medixlinx QR code for printed materials; and
   (5) Related routing-facing identifiers or references reasonably used by Medixlinx to support routing access, provider identification, handoff continuity, or participation within the protocol.
3. These routing-facing references are intended to direct patients or users to the appropriate Provider Page as the patient-facing destination. The Medixlinx protocol environment performs the underlying routing, validation, fit, and handoff functions in the background.
4. Medixlinx may determine the form, wording, placement guidance, linking destination, technical configuration, visual treatment, or usage conditions applicable to such routing-facing references.
5. Providers shall not materially alter, mislabel, misuse, disable, obscure, or repurpose Medixlinx routing-facing references in a manner that creates confusion regarding their destination, function, protocol identity, or routing role.
6. Each provider acknowledges that routing buttons, links, QR codes, and related routing-facing references are part of the Medixlinx participation structure and are intended to support deterministic routing access rather than ordinary advertising, directory placement, or generalized promotion.

§4.6. Page Status, Modification, Removal, and Non-Publication

1. Because the Provider Page is a required participation component, Medixlinx may create, publish, revise, narrow, suspend, unpublish, remove, or replace the Provider Page or associated participation materials where necessary to preserve accuracy, fit, participation status, or protocol integrity.
2. Medixlinx may take such action where it determines, in its discretion, that:
   (1) Page content or related materials are inaccurate, incomplete, misleading, or outdated;
   (2) Submitted materials are insufficient, unusable, or unauthorized;
   (3) The provider is not fit for continued routing in the form then in use;
   (4) Routing logic, setup status, or endpoint readiness does not support continued deployment;
   (5) Participation status has changed;
   (6) The provider has failed to respond to reasonable review, correction, or setup requests; or
   (7) Revision, suspension, or removal is otherwise necessary to preserve Medixlinx system integrity.
3. Medixlinx may also delay or withhold initial publication of a Provider Page or related participation material pending satisfactory completion of review, correction, setup, or routing-readiness requirements.
4. The required nature of the Provider Page does not eliminate Medixlinx’s authority to control whether a given page or related participation material is ready, accurate, appropriate, or fit for publication or continued deployment.
5. Where appropriate, Medixlinx may permit correction, resubmission, or later reconsideration of a revised, suspended, withheld, or removed page or participation material, but Medixlinx is not required to do so.
6. Each provider acknowledges that although a Provider Page is a required component of participation, its continued form, content, and deployability remain subject to Medixlinx control, accuracy requirements, routing integrity, and protocol standards.

§5.1. Setup Requirements and Participation Readiness

1. Participation in Medixlinx requires the completion of such setup steps, technical coordination, operational confirmations, and implementation requirements as Medixlinx determines are necessary to support routing integrity, handoff continuity, and provider readiness.
2. Setup may include, without limitation:
   (1) Confirmation of provider identity, scope, and routing-fit information;
   (2) Configuration of the Provider Page and associated participation materials;
   (3) Designation of intake endpoints, contact pathways, or handoff destinations;
   (4) Provision of forms, links, scheduling pathways, or intake instructions;
   (5) Testing of routing flow, redirection behavior, or handoff continuity; and
   (6) Such other implementation steps as Medixlinx reasonably requires for launch or continued participation.
3. A provider shall cooperate in good faith with Medixlinx during setup and shall provide timely, materially accurate, and sufficiently complete information needed for implementation.
4. Medixlinx may determine that a provider is not ready for launch, routing activation, or continued participation until setup requirements have been adequately completed.
5. Partial setup, delayed setup, or nominal setup shall not obligate Medixlinx to activate routing before Medixlinx determines that participation readiness has been achieved.
6. Each provider acknowledges that setup within Medixlinx is not a cosmetic onboarding formality, but a necessary part of establishing a functioning routing and handoff environment.

§5.2. Provider Endpoints and Handoff Destinations

1. Each provider shall supply or confirm the endpoint, destination, or handoff pathway through which appropriately routed users, patients, clients, or intake traffic are to be directed within the Medixlinx environment.
2. Such endpoints or destinations may include, without limitation:
   (1) A Provider Page destination;
   (2) A website pathway or provider-controlled page;
   (3) A scheduling page, booking path, or intake form;
   (4) A phone-based intake line or call destination;
   (5) An email-based intake destination, where permitted by Medixlinx;
   (6) A location-specific or service-line-specific intake path; or
   (7) Another destination or handoff structure approved by Medixlinx.
3. A provider shall ensure that any supplied endpoint or handoff destination is genuine, functional, appropriate for the relevant intake type, and materially consistent with the provider’s represented scope, availability, and routing conditions.
4. Medixlinx may reject, narrow, condition, or decline use of a proposed endpoint where Medixlinx determines that the endpoint is unreliable, unclear, inconsistent with protocol needs, unfit for the relevant intake type, or otherwise inadequate for routing integrity.
5. The existence of an endpoint does not by itself make it acceptable for Medixlinx purposes.
6. Each provider acknowledges that endpoint suitability is determined by Medixlinx relating to routing correctness, handoff clarity, and operational continuity, not solely by provider preference.

§5.3. Integration Inputs and Technical Cooperation

1. A provider shall supply such access information, implementation details, technical inputs, administrative confirmations, and operational cooperation as Medixlinx reasonably requires to establish, maintain, or revise participation.
2. Such cooperation may include, without limitation:
   (1) Confirming website or domain information relevant to routing-facing materials;
   (2) Implementing or permitting the use of a Medixlinx routing button or related linking reference;
   (3) Confirming destination URLs, forms, contact pathways, or public-facing intake references;
   (4) Supplying information needed for page configuration, routing continuity, or provider identification;
   (5) Responding to implementation questions, test findings, or correction requests; and
   (6) Coordinating with Medixlinx regarding setup dependencies reasonably affecting launch or continued routing use.
3. Providers shall not obstruct, delay, or materially complicate required setup or implementation steps through avoidable non-responsiveness, conflicting instructions, incomplete information, or repeated failure to confirm necessary details.
4. Medixlinx retains control over its own protocol environment, routing logic, provider-page structure, deployment methods, and implementation standards, and no provider shall acquire rights to Medixlinx's internal systems, repositories, prompt structures, deployment layers, or technical architecture merely by participating in the protocol.
5. Medixlinx may use such internal tools, systems, hosted environments, development layers, repositories, or implementation methods as it deems appropriate to operate the protocol, provided that providers are solely entitled to the participation and routing-facing outputs made available to them.
6. Each provider acknowledges that participation in Medixlinx may require technical cooperation without conferring ownership of, access to, or control over the underlying Medixlinx system environment.

§5.4. Testing, Validation, and Operational Readiness

1. Before launch, during setup, and during continuing participation, Medixlinx may test, validate, simulate, review, or otherwise examine routing flow, endpoint behavior, page function, handoff continuity, and related operational conditions.
2. Such testing or validation may include, without limitation:
   (1) Confirmation that the Provider Page functions as intended;
   (2) Confirmation that links, routing buttons, QR references, or redirection paths reach the correct destination;
   (3) Review of endpoint accessibility, clarity, or continuity;
   (4) Verification that routing outcomes remain consistent with represented provider fit;
   (5) Identification of technical or operational failure points; and
   (6) Staged or repeated testing where Medixlinx determines that additional validation is necessary.
3. A provider shall reasonably cooperate with testing and validation activities where provider confirmation, response, correction, or participation is needed.
4. Medixlinx may delay launch, suspend routing activation, narrow participation, or require corrective action where testing or validation reveals incomplete setup, endpoint unreliability, inaccurate destination logic, degraded continuity, or other operational concerns.
5. Successful setup activity at one point in time does not prevent Medixlinx from conducting later testing or later requiring renewed validation where circumstances change or integrity concerns arise.
6. Each provider acknowledges that testing and validation are necessary parts of deterministic routing infrastructure and not evidence of optional experimentation or non-committed participation by Medixlinx.

§5.5. Ongoing Endpoint Maintenance and Change Management

1. Each provider shall maintain the continued functionality, accessibility, and material accuracy of provider-controlled endpoints, handoff destinations, and related participation-facing references used in connection with Medixlinx.
2. A provider shall notify Medixlinx within a commercially reasonable time of any material change affecting:
   (1) Destination URLs, links, routing references, or QR-linked paths;
   (2) Scheduling pages, intake forms, contact pathways, or phone destinations;
   (3) Office status, service availability, territory coverage, or intake readiness;
   (4) Operational restrictions or changes affecting handoff suitability;
   (5) Website structure or public-facing routing references; or
   (6) Any other matter reasonably likely to affect routing continuity or destination correctness.
3. Providers shall not materially alter or replace a Medixlinx-relevant endpoint, destination, intake path, or routing-facing reference in a way that breaks continuity, creates confusion, or degrades routing function without timely notice to Medixlinx.
4. Medixlinx may require updated testing, revised setup steps, corrected references, or temporary routing limitation where provider-side changes materially affect operational continuity.
5. A provider’s failure to manage endpoint changes responsibly may be treated by Medixlinx as an operational integrity issue even where the provider’s underlying participation status has not otherwise changed.
6. Each provider acknowledges that endpoint maintenance and change management are continuing participation obligations and not one-time setup matters.

§5.6. Setup Failure, Degraded Function, and Routing Limitation

1. If setup is incomplete, implementation is materially delayed, an endpoint fails, a handoff path degrades, or operational continuity cannot be reasonably maintained, Medixlinx may limit, delay, suspend, narrow, or decline routing activity affected by the problem.
2. Medixlinx may take such action where, in its discretion:
   (1) Required setup has not been completed;
   (2) A provider has not supplied the necessary information, confirmations, or cooperation;
   (3) A proposed or active endpoint is nonfunctional, inconsistent, or unfit;
   (4) Routing continuity is broken or materially degraded;
   (5) Testing reveals operational unreliability;
   (6) Provider-side changes have disrupted implementation; or
   (7) Continued routing would otherwise risk mismatch, failed handoff, user confusion, or protocol degradation.
3. Medixlinx shall have no obligation to continue routing through a known-broken, degraded, incomplete, or unvalidated participation path merely because a provider has applied, been accepted, or previously launched.
4. Where appropriate, Medixlinx may permit cure, correction, retesting, or later restoration of routing, but Medixlinx is not required to do so on any fixed timeline or before it determines that operational integrity has been restored.
5. Limitations imposed under this Section may apply to the provider generally or only to the affected service category, routing path, endpoint, geography, intake type, or participation component.
6. Each provider acknowledges that setup failure or degraded function is not a minor administrative inconvenience within Medixlinx, but may directly affect routing integrity and may therefore justify immediate limitation, delay, suspension, or nonactivation of affected participation functions.

§6.1. Acceptance and Activation

1. A provider shall not be deemed accepted into Medixlinx merely by applying, submitting materials, communicating with Medixlinx, reviewing a Provider Page, participating in setup, or paying any amount unless and until Medixlinx affirmatively determines that the provider is accepted for participation.
2. Acceptance may be conditioned on completion of review, confirmation of fit, accuracy of submitted information, completion of setup, endpoint readiness, Provider Page readiness, and such other requirements as Medixlinx reasonably determines are necessary for participation.
3. Medixlinx may distinguish between acceptance for review, acceptance for setup, acceptance for limited participation, and full routing activation, and a provider shall not assume that progress at one stage guarantees advancement to another.
4. Routing activation may be limited by service line, geography, intake type, species, endpoint, operational condition, or other fit-related variable determined by Medixlinx.
5. Medixlinx may activate participation on a staged, conditional, narrowed, or test-based basis where it determines that such an approach better preserves routing integrity or operational correctness.
6. Each provider acknowledges that acceptance and activation within Medixlinx are controlled protocol determinations and not automatic consequences of application, interest, payment, or partial setup.

§6.2. No Obligation to Accept or Continue

1. Medixlinx has no obligation to accept any provider for participation, to activate any provider for routing, or to continue any provider’s participation for any minimum duration unless expressly stated by Medixlinx in writing.
2. A provider’s submission of materials, completion of forms, participation in meetings, cooperation during setup, or prior inclusion in Medixlinx does not create any right to acceptance, continued routing, uninterrupted participation, or indefinite maintenance of a Provider Page.
3. Medixlinx may decline to accept, may defer a decision regarding, or may decline to continue a provider where Medixlinx determines that participation is not appropriate, ready, accurate, reliable, or fit for the protocol.
4. Medixlinx is not required to preserve participation merely because a provider prefers to remain in the system, believes itself broadly relevant to a care category, or has previously been routed.
5. Nothing in this Agreement shall be interpreted to require Medixlinx to operate as a universal intake channel, broad provider access layer, or guaranteed participation environment.
6. Each provider acknowledges that continued participation in Medixlinx depends on ongoing fit, operational readiness, accuracy, and protocol integrity, and not on provider expectation alone.

§6.3. Suspension and Interim Limitation

1. Medixlinx may suspend, pause, narrow, condition, or otherwise limit a provider’s participation on an interim or partial basis where Medixlinx determines that immediate termination is unnecessary but continued unrestricted participation is not appropriate.
2. Such suspension or limitation may apply to:
   (1) The provider generally;
   (2) A specific Provider Page;
   (3) A service line, specialty, or care category;
   (4) A geography or routing territory;
   (5) A particular intake type or case type;
   (6) An endpoint, handoff path, or technical pathway; or
   (7) Any other participation component Medixlinx reasonably identifies as affected.
3. Medixlinx may impose suspension or interim limitation where, in its discretion:
   (1) Information appears inaccurate, incomplete, or outdated;
   (2) Fit integrity is degraded or uncertain;
   (3) Setup or endpoint function is incomplete, broken, or unreliable;
   (4) Provider responsiveness is materially insufficient;
   (5) Routing outcomes suggest mismatch, confusion, or operational strain;
   (6) A review, correction, or validation process is pending; or
   (7) Limitation is otherwise necessary to preserve Medixlinx protocol integrity.
4. Medixlinx may impose such measures with or without prior notice where Medixlinx determines that prompt action is reasonably necessary.
5. Where appropriate, Medixlinx may permit correction, clarification, cure, or later reinstatement, but Medixlinx is not required to do so before imposing or maintaining an interim limitation.
6. Each provider acknowledges that suspension and interim limitation are core protective tools within Medixlinx and do not require Medixlinx to wait for a total failure before acting.

§6.4. Grounds for Termination

1. Medixlinx may terminate a provider’s participation in whole or in part where Medixlinx determines that continued participation is no longer appropriate, reliable, or consistent with protocol integrity.
2. Grounds for termination may include, without limitation:
   (1) False, misleading, materially incomplete, or persistently outdated representations;
   (2) Failure to maintain fit, endpoint suitability, or operational readiness;
   (3) Repeated or uncured setup, routing, handoff, or continuity failures;
   (4) Misuse, mislabeling, or material alteration of Medixlinx participation materials or routing-facing references;
   (5) Failure to respond to reasonable requests for review, correction, validation, or coordination;
   (6) Provider conduct or operational conditions that create confusion, mismatch risk, failed handoff risk, or protocol degradation; or
   (7) Any other circumstance in which Medixlinx determines that termination is reasonably necessary to protect the system.
3. Termination may be immediate where Medixlinx determines that the issue is severe, repeated, uncured, structurally incompatible with the protocol, or otherwise unsuitable for continued participation.
4. Termination may be immediate where Medixlinx determines that the issue is severe, repeated, uncured, structurally incompatible with the protocol, or otherwise unsuitable for continued participation.
5. Termination may apply to the provider generally or only to the affected participation component, Provider Page, service category, routing path, territory, or operational function.
6. Each provider acknowledges that termination within Medixlinx is a protocol-protection measure and not a guarantee-triggered penalty requiring marketplace-style permanence or exposure continuity.

§6.5. Effect of Suspension or Termination

1. Upon suspension, limitation, nonactivation, or termination, Medixlinx may discontinue, remove, narrow, deactivate, unpublish, or otherwise restrict the affected routing paths, Provider Page elements, participation materials, or protocol-facing functions.
2. Such effects may include, without limitation:
   (1) Nonactivation or cessation of routing;
   (2) Narrowing or removal of relevant intake pathways;
   (3) Unpublication, revision, or removal of the Provider Page;
   (4) Disabling or discontinuation of routing-facing links, buttons, or QR references;
   (5) Cessation of use of affected provider-associated materials within Medixlinx; and
   (6) Such other steps as Medixlinx reasonably determines are appropriate to reflect the provider’s changed participation status.
3. A provider whose participation has been suspended or terminated shall not represent, imply, or hold itself out as currently active within Medixlinx beyond the extent, if any, expressly permitted by Medixlinx.
4. Medixlinx may retain internal records, historical materials, implementation records, and related participation documentation as reasonably necessary for operational, legal, archival, or system-integrity purposes.
5. Suspension or termination shall not obligate Medixlinx to continue publication, routing, maintenance, correction work, technical support, or participation-facing deployment for the affected provider.
6. Each provider acknowledges that the effect of suspension or termination may be immediate and operational, because Medixlinx functions as deterministic routing infrastructure rather than as a passive listing environment.

§6.6. Survival and Continuing Obligations

1. Termination, suspension, expiration, or non-continuation of participation does not eliminate any obligation which, by its nature, is intended to survive or remain relevant after active participation ends.
2. Without limitation, obligations relating to the accuracy of prior representations, authority of submitted materials, permitted use of Medixlinx references, non-misrepresentation of participation status, payment obligations already incurred, and protection of Medixlinx system integrity may survive to the extent applicable.
3. Medixlinx’s prior exercise or non-exercise of any right under this Agreement does not waive future exercise of that right.
4. Any prior acceptance, prior routing activity, prior publication, or prior operational tolerance by Medixlinx shall not prevent Medixlinx from later enforcing this Agreement where Medixlinx determines that enforcement has become necessary.
5. Providers remain responsible for statements they make regarding their participation in Medixlinx after suspension or termination and shall not imply an active relationship where none exists.
6. Each provider acknowledges that the end of active participation does not erase the legal or operational significance of what occurred during participation.